NCT01022736

Plasma Gabapentin Concentration During and Following Cardiac Bypass

Preemptive Gabapentin Administration and Perioperative Plasma Concentrations With Cardiac Bypass

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Queen's University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This open label investigation is to determine whether cardiopulmonary bypass affects plasma gabapentin concentration after preoperative administration in the setting of cardiac bypass surgery. Following signed informed consent, 16 patients scheduled for cardiac bypass surgery will be given gabapentin (600mg, oral) 1 hour prior to surgery, 1 hour following extubation and then every 8 hours for a total of 4 doses. Plasma gabapentin levels will be measured prior to induction, prior to bypass, 10 min into the bypass procedure, 10 minutes before separation from bypass, 30 minutes following bypass and then before and 2 hours following each of the next 3 doses of gabapentin. Pain scores, sedation scores, side effects and morphine equivalents will be documented for one day following surgery.

Conditions

• Cardiopulmonary Bypass

Interventions

Type	Name	Description
DRUG	Gabapentin	Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.

Timeline

• Start date: 2007-05-01
• Primary completion: 2007-09-01
• Completion: 2007-09-01
• First posted: 2009-12-01
• Last updated: 2009-12-08

Locations

1 site across 1 country: Canada